View ValuationCleo Diagnostics 将来の成長Future 基準チェック /06現在、 Cleo Diagnosticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長33.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • 3hNew major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$2.6m revenue, or US$1.8m). Market cap is less than US$100m (AU$49.3m market cap, or US$34.4m).お知らせ • Dec 18Cleo Diagnostics Ltd has completed a Follow-on Equity Offering in the amount of AUD 5 million.Cleo Diagnostics Ltd has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,333,334 Price\Range: AUD 0.6 Transaction Features: Subsequent Direct ListingNew Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$845k revenue, or US$563k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$91.2m market cap, or US$60.8m).分析記事 • Sep 10Companies Like Cleo Diagnostics (ASX:COV) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Sep 06Cleo Diagnostics Ltd, Annual General Meeting, Nov 24, 2025Cleo Diagnostics Ltd, Annual General Meeting, Nov 24, 2025.New Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$211k revenue, or US$127k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$48.8m market cap, or US$29.5m).お知らせ • Oct 04Cleo Diagnostics Ltd, Annual General Meeting, Nov 27, 2024Cleo Diagnostics Ltd, Annual General Meeting, Nov 27, 2024. Location: level 33, 477 collins street, melbourne vic 3000 Australia分析記事 • Sep 16Cleo Diagnostics (ASX:COV) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, Cleo Diagnostics...お知らせ • Sep 23Cleo Diagnostics Ltd, Annual General Meeting, Nov 22, 2023Cleo Diagnostics Ltd, Annual General Meeting, Nov 22, 2023, at 16:00 AUS Eastern Standard Time.Board Change • Aug 22Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 19Cleo Diagnostics Ltd has completed an IPO in the amount of AUD 12 million.Cleo Diagnostics Ltd has completed an IPO in the amount of AUD 12 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.2 Discount Per Security: AUD 0.012 Security Features: Attached Options このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cleo Diagnostics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ASX:COV - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20253-4-3-3N/A9/30/20252-4-3-3N/A6/30/20251-4-3-3N/A3/31/20251-4-3-3N/A12/31/20240-3-3-3N/A9/30/20240-3-2-2N/A6/30/20240-4-2-2N/A3/31/20240-4-2-2N/A12/31/2023N/A-4-2-2N/A9/30/2023N/A-3-1-1N/A6/30/2023N/A-2-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: COVの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: COVの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: COVの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: COVの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: COVの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 21:45終値2026/07/17 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cleo Diagnostics Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • 3hNew major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$2.6m revenue, or US$1.8m). Market cap is less than US$100m (AU$49.3m market cap, or US$34.4m).
お知らせ • Dec 18Cleo Diagnostics Ltd has completed a Follow-on Equity Offering in the amount of AUD 5 million.Cleo Diagnostics Ltd has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,333,334 Price\Range: AUD 0.6 Transaction Features: Subsequent Direct Listing
New Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$845k revenue, or US$563k). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$91.2m market cap, or US$60.8m).
分析記事 • Sep 10Companies Like Cleo Diagnostics (ASX:COV) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Sep 06Cleo Diagnostics Ltd, Annual General Meeting, Nov 24, 2025Cleo Diagnostics Ltd, Annual General Meeting, Nov 24, 2025.
New Risk • Apr 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (AU$211k revenue, or US$127k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (AU$48.8m market cap, or US$29.5m).
お知らせ • Oct 04Cleo Diagnostics Ltd, Annual General Meeting, Nov 27, 2024Cleo Diagnostics Ltd, Annual General Meeting, Nov 27, 2024. Location: level 33, 477 collins street, melbourne vic 3000 Australia
分析記事 • Sep 16Cleo Diagnostics (ASX:COV) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, Cleo Diagnostics...
お知らせ • Sep 23Cleo Diagnostics Ltd, Annual General Meeting, Nov 22, 2023Cleo Diagnostics Ltd, Annual General Meeting, Nov 22, 2023, at 16:00 AUS Eastern Standard Time.
Board Change • Aug 22Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 19Cleo Diagnostics Ltd has completed an IPO in the amount of AUD 12 million.Cleo Diagnostics Ltd has completed an IPO in the amount of AUD 12 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.2 Discount Per Security: AUD 0.012 Security Features: Attached Options